Professor Mégraud and colleagues from France determined the prevalence of gastrointestinal (GI) symptoms.
The researcher team assessed patients with and without Helicobacter pylori treated with non-steroidal anti-inflammatory drugs (NSAIDs).
The researchers estimated the impact of H pylori eradication on these symptoms.
The team conducted a multicenter, community-based, randomized, case-control study.
Patients presenting with a rheumatic disorder motivating the prescription of an NSAID for at least 2 weeks were stratified in 2 groups by a serological doctor test.
The patients tested as H pylori-positive or H pylori-negative.
H pylori-positive patients were further divided further into 2 subgroups.
|GI symptoms were present in 58% at week 2 in Group 1 vs 41% in Group 2|
|American Journal of Gastroenterology|
Patients in Group 1 received either an eradication treatment or a placebo in Group 2.
The main outcome measure was the prevalence of GI symptoms estimated in
Groups 1 and 2 and in noninfected patients in Group 3 at weeks 2, 6, and 12.
Among 145 H pylori-negative patients, GI symptoms were present in 43%, 21%, and 10% at weeks 2, 6, and 12, respectively.
The team found that in Group 1 and 2, GI symptoms were present in 58% at week 2, 25% at week 6, and 9% at week 12.
The researchers observed that in Group 2, GI symptoms were present in 41% at week 2, 23% at week 6, and 17% at week 12.
The prevalence of GI symptoms at week 2 was similar in the placebo and in the H pylori-negative group.
The team noted that the highest prevalence of symptoms at week 2 in Group 1 was essentially due to diarrhea.
The prevalence of GI symptoms was the same for Groups 1 and 3 at week 12.
In addition, the researchers observed that GI symptoms were higher in Group 2, but the difference did not reach statistical significance.
Professor Mégraud's team concluded, “The short-term 6 week GI tolerance of conventional NSAIDs does not differ whether or not the patients are infected by H pylori.”
“The tendency observed for the medium 12 week term deserves to be confirmed.”